[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricular-systolic-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricular-systolic-dysfunction":173},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,66,78,100,121,149],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053407",false,"NCT05714085","Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)","A Phase 2\u002F3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)","Inclusion Criteria:\n\n* Has symptomatic chronic heart failure (HF) resulting from systemic left ventricular (LV) systolic dysfunction.\n* Has biventricular physiology with a morphologic systemic left ventricle.\n* Is currently receiving stable medical therapy for HF.\n* Has left ventricular ejection fraction (LVEF) \\\u003C45% assessed within 3 months before randomization.\n* Is of any sex\u002Fgender, from \\>28 days to \\\u003C18 years of age inclusive. Must weigh ≥3 kg to participate.\n* Female is eligible to participate if not pregnant or breastfeeding, and at least one of the following: is not a participant of childbearing potential (POCBP); or is a POCBP who uses a highly effective contraceptive method; has a negative highly sensitive pregnancy test; abstains from breastfeeding during the study intervention period and for at least 30 days after study intervention; and their medical history; their menstrual history, and recent sexual activity has been reviewed.\n* Extension Period: Was randomized, received at least 1 dose of study intervention (vericiguat or placebo), did not permanently discontinue study intervention, and completed the Week 52 visit and safety follow-up period of the Base Period\n\nExclusion Criteria:\n\n* Is clinically unstable-with at least one of the following: has symptomatic hypotension or is hypotensive for age, recent use of intravenous (IV) inotrope and\u002For IV vasodilator, or recent IV diuretic.\n* Has a known allergy or sensitivity to vericiguat, any of its constituents, or any other soluble guanylate cyclase (sGC) stimulator.\n* Has a history of single ventricle heart disease or has a morphologic systemic right ventricle.\n* Has undergone heart transplantation, is awaiting heart transplantation United Network for Organ Sharing (UNOS) Class 1A or equivalent, is receiving continuous IV infusion of an inotrope, or has an implanted ventricular assist device.\n* Has sustained or symptomatic dysrhythmia uncontrolled with drug or device therapy.\n* Has had recent cardiovascular (CV) surgical procedure or percutaneous intervention to palliate or correct congenital CV malformations.\n* Has unoperated or residual hemodynamically significant congenital cardiac malformations.\n* Has hypertrophic or restrictive cardiomyopathy.\n* Has active myocarditis or has been recently diagnosed with presumed or definitive myocarditis.\n* Has acute coronary syndrome, undergone recent coronary intervention, or indication for coronary revascularization.\n* Has symptomatic carotid stenosis or other symptomatic cerebrovascular disease\n* Has severe pulmonary hypertension.\n* Requires continuous home oxygen for significant pulmonary disease and\u002For has known interstitial lung disease.\n* Has severe chronic kidney disease.\n* Has hepatic disorder such as hepatic encephalopathy, hepatic laboratory abnormalities or Child Pugh Class C.\n* Has a gastrointestinal or biliary disorder that could impair absorption, metabolism, or excretion of medications.\n* Has significant bone disease (other than osteopenia) that in the assessment of the investigator can alter bone formation\n* Has concurrent or anticipated concomitant use of phosphodiesterase type 5 inhibitors or an sGC stimulator.\n* Has received a COVID-19 vaccination within 1 week before randomization.","ALL","29 Days","17 Years",{"count":19,"type":20},342,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.",[27,28],"Heart Failure","Left Ventricular Systolic Dysfunction","RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2023-05-31",{"date":37,"type":20},"2032-04-15",{"name":39,"class":40},"Merck Sharp & Dohme LLC","INDUSTRY",107,{"id":43,"slug":4,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100607776","NCT07192952","A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction","A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)","FIORELLO","Inclusion Criteria:\n\n* For participants rolling over from randomized controlled trial (RCT): Prior participation in the finerenone Phase 3 study FIORE (21466) and not permanently discontinued from the study intervention prior to the end of treatment (EoT) visit in FIORE.\n* For newly enrolled infants \\\u003C6 months of age: Left ventricular systolic dysfunction (LVSD) with left ventricular ejection fraction (LVEF) ≤ 50% at screening assessed by echocardiography.\n* For newly enrolled infants \\\u003C6 months of age: Elevated NT-pro BNP levels (\\> 500 mg\u002FL) at screening.\n* For newly enrolled infants \\\u003C6 months of age: Heart failure (HF) etiologies include congenital heart defects (CHD) with biventricular physiology and systemic LV; idiopathic cardiomyopathy (CM); familial\u002Finherited and\u002For genetic CM; history of myocarditis (diagnosis of an acute episode at least 3 months prior to treatment assignment); neuromuscular disorder; inborn error of metabolism; mitochondrial disorder; acquired (chemotherapy, iatrogenic, infection, rheumatic, or nutritional); ischemic (e.g., Kawasaki disease and postoperative HF); LV noncompaction.\n* For newly enrolled infants \\\u003C6 months of age: Receiving standard of care (SoC) treatment for heart failure according to local guidelines or investigator´s discretion (on a stable regimen for 30 days before baseline).\n* Newly enrolled newborns and infants \\\u003C 6 months of age must have a body weight of ≥3 kg at Visit 1.\n\nExclusion Criteria:\n\n* For participants rolling over from randomized controlled trial (RCT): To roll-over to FIORELLO, all participants: Potassium (K+) \\>5.5 mmol\u002FL. After unblinding:\n\n  * For participants who received finerenone in FIORE: K+ \\>5.5 mmol\u002F L\n  * For participants who received placebo in FIORE: K+ \\>5.0 mmol\u002FL for children ≥2 years of age, and \\>5.3 mmol\u002FL for children \\\u003C2 years of age (if eGFR is \\\u003C60 mL\u002Fmin\u002F1.73m² for participants \\\u003C2 years of age, the serum potassium threshold of \\>5.0 mmol\u002FL will be used for exclusion)\n* For newly enrolled newborns and infants \\\u003C 6 months of age: Potassium ≥ 5.3 mmol\u002Fl (if eGFR is \\\u003C60 mL\u002Fmin\u002F1.73m², the serum potassium threshold of \\>5.0 mmol\u002FL will be used for exclusion).\n* For participants rolling over from RCT: Severe renal dysfunction with estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m² at FIORE EoT or Visit 1.\n* For newly enrolled infants \\\u003C 6 months of age: Severe renal dysfunction with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2 at screening or Visit 1.\n* Treatment with a mineralocorticoid receptor antagonist, other than the study intervention, (e.g., spironolactone, eplerenone) within 30 days of Visit 1.\n* Requirement of any intravenous (IV) vasoactive agents; mechanical ventilation; mechanical circulatory support; sustained or symptomatic arrhythmias not controlled by drug or device therapy within 30 days prior to study treatment.","18 Years",{"count":51,"type":20},117,[24],"Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure with left ventricular systolic dysfunction (LVSD) is a condition where the left side of the heart is weak and struggles to pump blood effectively, leading to symptoms like shortness of breath, fatigue, and poor growth.\n\nThe study treatment, finerenone (also called BAY94-8862), is under development to treat newborns, children, and young adults with heart failure and LVSD. It works by blocking a protein that contributes to inflammation, scarring, and thickening in the heart and blood vessels, which may help the heart pump more blood effectively.\n\nThe main purpose of this study is to learn about how safe finerenone is and how well it works in the long-term treatment of heart failure and LVSD.\n\nTo understand how safe the treatment is, the study team will gather information on the number of patients who experience medical problems after taking finerenone, also known as \"treatment emergent adverse events\" (TEAEs). Additionally, they will collect blood samples to measure levels of an electrolyte called potassium and monitor blood pressure. They will also assess kidneys function using the estimated glomerular filtration rate (eGFR).\n\nIn this study, which is an extension of the earlier done FIORE study, finerenone will also be studied in newly enrolled newborns under 6 months with heart failure and LVSD and children and young adults from the FIORE study. The participants will be aged from newborns up to 18 years. All the participants will continue to receive their standard treatment as routine care for heart failure, along with finerenone during the study.\n\nThe participants will be in the study for around 10 to 11 months, depending on whether they rolled-over from the FIORE study or are newly enrolled newborns and infants \\\u003C6 months of age. They will take study treatment for up to 9 months. During this period, at least 6 visits are planned for participants. During these visits, the study team will:\n\n* have their blood pressure, heart rate, temperature, respiratory rate, height and weight measured\n* have blood samples taken\n* have physical examinations\n* have their heart examined by an electrocardiogram and echocardiography\n* answer questions about their medication and whether they have any adverse events, or have their parents or guardians' answer\n* for newborns and infants, evaluate the acceptability of the study drug formulation through parents or guardians' feedback.\n\nAn adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.\n\nThe doctors will check the participants' health a month after the participants take their last treatment.",[28,55],"Heart Failure (Pediatric)","2026-06-26",{"date":58,"type":33},"2026-06-29",{"date":60,"type":33},"2026-06-01",{"date":62,"type":20},"2030-12-30",{"name":64,"class":40},"Bayer",132,{"id":67,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":68,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":25,"conditions":70,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":76,"locationsCount":77},"100494123",{"count":19,"type":20},[23,24],[27,28],"2026-06-17",{"date":73,"type":33},"2026-06-22",{"date":35,"type":33},{"date":37,"type":20},{"name":39,"class":40},106,{"id":79,"slug":4,"hasResults":10,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":10,"sex":15,"minAge":85,"maxAge":17,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100607457","NCT07188805","A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction","A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Efficacy, Safety, and PK\u002F PD of Finerenone, in Addition to Standard-of-care, in Pediatric Patients, 6 Months to \u003C 18 Years of Age With Heart Failure (HF) and Left Ventricular Systolic Dysfunction (LVSD)","FIORE","Inclusion Criteria:\n\n* Participants must be 6 months to \\\u003C18 years old at the time when the informed consent\u002Fassent is signed.\n* Left ventricular systolic dysfunction (LVSD) with left ventricular ejection fraction (LVEF) ≤ 50% at screening assessed by echocardiography.\n* Elevated NT-pro BNP levels\n\n  * \\>500 ng\u002Fl for children ≥ 6 months to \\\u003C 2 years of age\n  * \\>300 ng\u002Fl, for children ≥ 2 years to \\\u003C18 years\n* Heart failure etiologies including congenital heart defects (CHD) with biventricular physiology and systemic LV; idiopathic cardiomyopathy (CM); familial\u002Finherited and\u002For genetic CM; history of myocarditis (diagnosis of an acute episode was at least 3 months prior to randomization); neuromuscular disorder (eg, duchenne muscular dystrophy); inborn error of metabolism; mitochondrial disorder; acquired (chemotherapy, iatrogenic, infection, rheumatic, or nutritional); ischemic (eg, Kawasaki disease and postoperative heart failure \\[HF\\]); LV noncompaction.\n* Receiving standard of care (SoC) treatment for heart failure according to local guidelines or investigator´s discretion and being on a stable regimen for 30 days prior to randomization.\n* Study participants must have a body weight ≥ 4.0 kg at Visit 1.\n\nExclusion Criteria:\n\n* Serum potassium:\n\n  * \\> 5.0 mmol\u002FL for children ≥ 2 years of age at either screening or randomization visit\n  * \\> 5.3 mmol\u002FL for children ≥ 6 months to \\\u003C 2 years of age at either screening or randomization visit (if estimated glomerular filtration rate \\[eGFR\\] \\\u003C 60 mL\u002Fmin\u002F1.73m², threshold of \\> 5.0 mmol\u002FL will be used)\n* Severe renal dysfunction with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m² at screening or randomization visit.\n* Systolic blood pressure (SBP) \\\u003C 5th percentile for age, sex and height at screening or randomization.\n* Sustained or symptomatic arrhythmias not controlled by drug or device therapy within 30 days prior to randomization.\n* Treatment with a mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone) within 30 days of randomization.\n* Requirement of any intravenous (IV) vasoactive agents, mechanical ventilation, mechanical circulatory support within 30 days prior to randomization.\n* Recent surgical procedure or other intervention to correct or palliate CHD within 3 months prior to randomization or anticipated to undergo cardiac surgery during the 3 months after randomization.","6 Months",{"count":87,"type":20},111,[24],"Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure is a serious condition where the heart is unable to pump enough blood to meet the body's needs. This can lead to symptoms like shortness of breath, fatigue, and poor growth in children.\n\nThe study treatment, finerenone (also called BAY94-8862), works by blocking a protein involved in inflammation, scarring, and thickening of the heart and blood vessels. This may help the heart to pump blood more effectively. This is the first study to explore its use specifically for children with heart failure and LVSD.\n\nThe main purpose of this study is to learn if finerenone works to help the heart compared to placebo in children with heart failure and LVSD. For this, the researchers will collect and analyze data on the levels of a protein called NT-proBNP in the blood, which indicates heart stress, and monitor the safety of the treatment.\n\nThe study will include children with heart failure and LVSD aged from 6 months to less than 18 years. The study participants will be randomly assigned to one of two treatment groups. Based on their group, they will receive either finerenone or a placebo for a duration of 3 months. A placebo looks like a treatment but does not have any medicine in it. Throughout the study, all participants will continue to receive their standard heart failure treatments.\n\nAt the start of this study, the doctors will check each participant's medical history and current medications. If participants qualify for the treatment phase, they will undergo treatment for about 90 days. During this time, they will visit the study site at least 3 times. During these visits, the participants will:\n\n* have their blood pressure, heart rate, temperature, respiratory rate, height and weight measured\n* have their heart examined by electrocardiogram (ECG) and echocardiogram\n* have blood samples taken\n* have physical examinations\n* answer questions about their medication and whether they have any adverse events, or have their parents or guardians' answers\n\nAn adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.\n\nAfter the initial three-month study, eligible participants will have the option to join a nine-month open-label extension study where all will receive finerenone. Participants who choose not to enroll in the extension will have a follow-up visit 30 days after their last treatment.",[28,55],"2026-06-12",{"date":93,"type":33},"2026-06-15",{"date":95,"type":33},"2025-11-19",{"date":97,"type":20},"2029-12-30",{"name":64,"class":40},133,{"id":101,"slug":4,"hasResults":10,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":120},"100575267","NCT06770062","Multimodality Evaluation of Left Ventricular Remodeling In Mitral Regurgitation: A Pilot Study","Inclusion Criteria:\n\n* Age \\>= 18\n* Male or Female\n* A diagnosis of severe chronic primary mitral regurgitation\n* Undergoing isolated robotic mitral annuloplasty at Mayo Clinic Rochester\n* Patients must have the ability to consent or have an appropriate representative available to do so.\n\nExclusion Criteria:\n\n* Prior valve intervention,\n* Concomitant valve surgery at the time of mitral annuloplasty (e.g. tricuspid annuloplasty, aortic valve replacement).\n* Concomitant \\>= moderate regurgitation or stenosis in any other valve by preoperative echocardiography\n* History of prior myocardial infarction\n* History of cardiomyopathy unrelated to mitral regurgitation (e.g. dilated, hypertrophic, infiltrative)\n* Pregnancy. Women of childbearing potential will be verbally screened by clinical staff during as part of routine pre-MRI evaluation. If a subject is unsure whether they could be pregnant, a negative pregnancy test will be performed prior to scanning.\n* Implantable devices that would be a contraindication to MRI\n* Severe allergy to gadolinium MRI contrast",{"count":106,"type":20},30,"OBSERVATIONAL","The purpose of this research is to determine the feasibility of a larger, future study proposing a multimodal approach using cardiac CT and MRI to assess the risk of developing left ventricular (LV) systolic dysfunction in patients with mitral regurgitation (MR).",[28],"2026-02-27",{"date":112,"type":33},"2026-03-03",{"date":114,"type":33},"2025-01-20",{"date":116,"type":20},"2027-12",{"name":118,"class":119},"Mayo Clinic","OTHER",1,{"id":122,"slug":4,"hasResults":10,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":120},"100536874","NCT06270498","Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure","Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure: a Randomized, Placebo-controlled Trial (RISE-HF)","RISE-HF","Inclusion Criteria:\n\n1. Chronic HF (New York Heart Association \\[NYHA\\] functional class II-IV) patients, on optimal therapy, and clinically stable for at least 4 weeks with no dose changes of HF drugs\n2. LVEF\\\u003C50% at screening visit (historical value can be used if performed within 6 months of screening visit)\n3. Either a documented hospitalization for HF in the previous 12 months of enrolment or an elevated NT-proBNP: ≥250 pg\u002FmL (or BNP ≥75 pg\u002FmL) for patients in normal sinus rhythm; ≥1,000 pg\u002FmL (or BNP ≥400 pg\u002FmL) for patients in atrial fibrillation\n4. TSAT \\\u003C20%\n5. Hemoglobin 10.0-16.0 g\u002FdL\n6. Rapid iron repletion with intravenous iron is not considered a clinical necessity by physicians after reviewing patient medical record (if anaemia is present, its grade is no more than mild)\n7. Age ≥18 years, male and female\n8. Willingness to provide informed consent\n9. Subjects who decide to use single or dual contraceptive methods to avoid conceiving during the study period\n\nExclusion Criteria:\n\n1. Neuromuscular, orthopedic or other non-cardiac condition that prevents the patient from exercise testing\n2. Exercise training program in the previous 3 months, or planned in the next 3 months\n3. Recent (\\\u003C3 month) acute coronary syndrome, coronary artery bypass surgery, percutaneous coronary interventions, transient ischemic attack, or stroke\n4. Severe valvular disease, hypertrophic obstructive cardiomyopathy, restrictive or constrictive cardiomyopathy, acute myocarditis\n5. Atrial fibrillation or flutter with a ventricular response rate of \\>100 beats per minute at rest\n6. Temperature ≤38 °C (oral or equivalent) or active infection as defined by current use of oral or intravenous antimicrobial agents\n7. Need for blood transfusion within the last month\n8. Hb\\\u003C10 g\u002FdL or Hb\\>16 g\u002FdL\n9. Rapid iron repletion with intravenous iron is considered a clinical necessity by physicians after reviewing patient medical record\n10. Documented active gastrointestinal bleeding\n11. Oral iron, i.v. iron or erythropoietin stimulating agent within the last 3 months\n12. eGFR ≤15 mL\u002Fmin or on hemodialysis\n13. Chronic liver disease and\u002For alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range\n14. Active cancer\n15. Evidence of iron overload (ferritin \\>400 ng\u002FmL)\n16. Hypersensitivity to any of the study products or known severe allergies\n17. Participation in another study\n18. Low body weight (≤35 kg)\n19. Known or anticipated pregnancy in the next 4 months\n20. Need for forbidden medications\n21. Breastfeeding\n22. Consumption of iron-rich foods or any food that alter iron absorption (i.e. food rich in vitamin C) due to dietary requirements\n23. Any pathological condition or disease associated with a reduction or an impairment of intestinal iron absorption (i.e., prior gastrectomy, atrophic gastritis, bariatric surgery, coeliac disease)",{"count":129,"type":20},60,[131],"PHASE4","The goal of this study is to investigate the effect of oral sucrosomial iron on exercise capacity and quality of life in patients with heart failure (HF) and iron deficiency (ID).\n\nThe main question the study aims to answer is whether oral sucrosomial iron improved exercise capacity, assessed by six-minute walk test, and quality of life, assessed by Kansas City Cardiomyopathy Questionnaire, compared with placebo.\n\nOne group of participants will receive treatment with oral sucrosomial iron and the other group will receive treatment with placebo.",[134,135,28],"Chronic Heart Failure","Iron-deficiency",[137,138,139],"heart failure","iron deficiency","sucrosomial iron","2025-09-25",{"date":142,"type":33},"2025-10-01",{"date":144,"type":33},"2024-03-14",{"date":146,"type":20},"2026-06-14",{"name":148,"class":119},"Raffaele De Caterina",{"id":150,"slug":4,"hasResults":10,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100362020","NCT03993730","Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy","CMR GUIDE DCM","Inclusion Criteria:\n\n* Age greater than\u002Fequal to 18 years old\n* Non-ischemic cardiomyopathy of dilated type\n* Left Ventricular Ejection Fraction \\\u003C 45%\n* Able and willing to comply with all pre, post and follow-up testing and requirements\n* On maximum tolerated doses of angiotensin converting enzyme (ACE) inhibitors (or Angiotensin Receptor Blockers(ARB) or Neprilysin Inhibitors) and Beta Blockers\n\nExclusion Criteria:\n\n1. Known coronary artery disease (CAD) (History of Myocardial Infarction or Significant Epicardial CAD on Angiography)\n2. Hypertrophic Cardiomyopathy\n3. Cardiomyopathy related to sarcoidosis\n4. Arrhythmogenic Right Ventricular Dysplasia\n5. Standard LGE CMR contraindications (e.g. severe claustrophobia, metal)\n6. Currently implanted permanent pacemaker and\u002For pacemaker\u002FICD lead\n7. Clinical indication for ICD or pacemaker or Cardiac Resynchronisation Therapy\n8. Contraindications to intravenous Gadolinium\n9. Severe renal insufficiency (eGFR\\\u003C 45mls\u002Fmin\u002F1.73m2 )\n10. New York Heart Association Heart Failure functional class IV\n11. Conditions associated with life expectancy \\\u003C1 year\n12. Pregnancy or in females of child-bearing potential, the non-use of accepted forms of contraception",{"count":156,"type":20},1880,[158],"NA","CMR GUIDE DCM is a randomized controlled trial with a registry for non-randomized patients.\n\nPatients enrolled will have non-ischemic cardiomyopathy (NICM) with mild to severe Left Ventricular (LV) systolic dysfunction with replacement fibrosis identified on Cardiac Magnetic Resonance (CMR).\n\n954 patients will be randomised from 50 sites across 4-6 countries worldwide to receive an implantable defibrillator (ICD) or implantable loop recorder (ILR).\n\nDevice and clinical follow-up will be performed at 3, 6, 12, 24, 36 months and at end of study.",[161,28,162],"Dilated Cardiomyopathy","Fibrosis Myocardial","NOT_YET_RECRUITING","2019-06-20",{"date":166,"type":33},"2019-06-21",{"date":168,"type":20},"2020-06",{"date":170,"type":20},"2026-06",{"name":172,"class":119},"Flinders University",""]